ReviewDiabetes, obesity & metabolism2025
iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.
Review in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.Diabetes, obesity & metabolism · 2026Trial
- iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.Diabetes, obesity & metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five years ago, the overall prevalence of diabetes in China was reported to be as high as 10.6%, and it is especially concerning that type 2 diabetes (T2DM) is developing in younger age groups. Glycaemic control rates (both HbA1c and post-prandial glucose control) are worryingly low among patients with T2DM in China, and 'clinical inertia' is a major challenge, in particular a reluctance among clinicians to initiate injectable therapy when oral antidiabetic therapies (OADs) are no longer achieving target levels of glucose control. Within the Chinese guidelines, clinicians now have the option to use a fixed-ratio combination of basal insulin (Glargine) and GLP-1 receptor agonist (lixisenatide), iGlarLixi, as a convenient, safe, and effective treatment for patients with T2DM. This review summarises the key clinical trials with iGlarLixi in Chinese and Asia-Pacific people, for example, the LixiLan-O-AP and LixiLan-L-CN trials, and highlights the advantages of this treatment for lowering HbA1c and post-prandial glucose. iGlarLixi is preferable to premixed insulin and can be combined with OADs among typical people with T2DM and poor glycaemic control. The safety, efficacy, and practical convenience of iGlarLixi are summarised in the Chinese healthcare context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.